Anju Welcomes Atherion Bioresearch as the Newest CRO Partner
Anju has announced a strategic partnership with Atherion Bioresearch, a full-service CRO. This collaboration provides both organizations opportunities to accelerate growth, streamline processes, and enhance data integrity.
Atherion Bioresearch selected Anju as a preferred partner due to Anju's eClinical solutions, industry knowledge, and their shared dedication to advancing the field of clinical research. Atherion possesses capabilities in diagnostics and therapeutics, as well as drug chemistry and manufacturing.
"This is a monumental step forward," said Michael Rosol, CEO at Atherion Bioresearch in a press release. "We are thrilled to combine our strengths and leverage Anju's cutting-edge solutions. This partnership will empower us to deliver even more efficient, compliant, and patient-centric clinical trials."
Paul Sahargun, SVP of eClinical at Anju, commented in a press release, "We look forward to this new partnership with Atherion. Through our combined resources we can redefine the standard for data integrity, operational efficiency, and patient-focused clinical trials."
Anju will serve Atherion in the advancement of therapeutic and diagnostic trials, including those focused on radiotherapeutics and in indications including oncology, inflammation and immunology, respiratory medicine, and ophthalmology.
Reference
Anju Welcomes Atherion Bioresearch as the Newest CRO Partner. (2023, October 31). Cision PR Newswire.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
